A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib
| Autor: | Manuel Cano-Marron, Joan Antoni Schoenenberger-Arnaiz, Pilar Taberner Bonastre, Gisela Torres Vicente, Eva Sese Abizanda, Tania Dalila Volta Pardo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Severe disease Case Report Disease Antibodies Monoclonal Humanized 030226 pharmacology & pharmacy Asymptomatic Inflammatory bowel disease Vedolizumab 03 medical and health sciences 0302 clinical medicine Immune system Piperidines Internal medicine medicine Humans 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Tofacitinib business.industry Middle Aged medicine.disease Ulcerative colitis Pyrimidines Colitis Ulcerative medicine.symptom business medicine.drug |
| Zdroj: | Eur J Hosp Pharm |
| ISSN: | 2047-9956 |
| Popis: | Ulcerative colitis (UC) is an inflammatory bowel disease of autoimmune origin with an estimated prevalence in Spain of 0.39%. Current treatments for UC do not achieve high long-term efficacy. Treatment recommendations in moderate and severe disease involve drugs, but when these options fail, the alternatives are scarce, and surgery is intended to be reserved for the last option. We present the case of a 48-year-old male patient with UC for 23 years, who had failed several lines of treatment. The patient started combined therapy with tofacitinib and vedolizumab. These drugs have different mechanisms of action, achieving an immune response and reducing gastrointestinal inflammation. The patient's disease symptoms improved 11 months after starting this treatment, and he is now entirely asymptomatic. Analytical parameters related to the disease have also shown improvement, and the patient has so far avoided the need for surgical intervention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|